SOUTH SAN FRANCISCO, Calif., April 18, 2016 /PRNewswire/ -- Profusa, Inc., a leading developer of tissue-integrated biosensors, today announced that Bradley W. Rice, Ph.D., joined the company as vice president of engineering R&D, responsible for fluorescence-based detection devices and tissue optics research. With more than 32 years of experience in advanced optical detection technologies, including 16 years in tissue optics, Dr. Rice led the development of IVIS® imaging technology, the gold standard for luminescent imaging used in pre-clinical research.
"We welcome Dr. Rice as the newest member of our executive team," said Ben Hwang, Ph.D., Profusa's chairman and chief executive officer. "His extensive experience gained through technical leadership positions within top life science companies will be vital in the development of our tissue-integrated biosensor technology."
Prior to joining Profusa, Dr. Rice served as senior vice president of systems R&D at Caliper Life Sciences and senior director of systems R&D at PerkinElmer. Previously, he was chief technology officer and vice president of R&D at Xenogen Corp. where he developed and co-invented the IVIS® series of luminescent imaging systems that allow life science researchers to non-invasively observe and monitor living cells in animal models.
Early in his career, he worked for 15 years as a staff scientist at Lawrence Livermore National Laboratory developing optical and microwave-based diagnostic instrumentation in the magnetic fusion energy program. He received a B.A. in physics from Colorado College, an M.S. in electrical engineering from the University of Wisconsin-Madison, and a Ph.D. in applied science from the University of California at Davis. He is an author of more than 50 peer-reviewed journal publications and an inventor on 34 issued patents.
Profusa, Inc., based in South San Francisco, Calif., is leading the development of a new generation of tissue-integrated sensors that empowers an individual with the ability to monitor their unique body chemistry in unprecedented ways to transform the management of personal health and disease. Overcoming the body's response to foreign material for long-term use, its technology promises to be the foundational platform of real-time biochemical detection through the development of tiny bioengineered sensors that become one with the body to detect and continuously transmit actionable, medical-grade data for personal and medical use.
See http://www.profusa.com for more information.
SOURCE Profusa, Inc.